SCHEMBL5205197

SCHEMBL5205197

CCOC(=O)C(CC)(Cc1ccc(OCc2ccccc2)cc1)Oc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
LMNA P02545 1/20 0.51
PPARA Q07869 4/20 0.49
PPARD Q03181 3/20 0.49
NR1H4 Q96RI1 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ALOX5 P09917 2/20 0.48
FFAR1 O14842 4/20 0.48
FFAR4 Q5NUL3 2/20 0.48
LTB4R Q15722 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205474 0.97 LMNA (0.49) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL5123841 0.88 PPARA (0.45) PPARGLMNAPPARAPPARDALDH1A1
SCHEMBL6713228 0.85 PPARG (0.53) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL2807182 0.84 PPARG (0.55) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL14311455 0.82 NR4A2 (0.53) PPARGPPARAPPARDFFAR1FFAR4
SCHEMBL14176244 0.81 LMNA (0.54) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL5213397 0.81 PPARG (0.52) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL6504864 0.81 MMP8 (0.63) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL15669148 0.81 L3MBTL1 (0.56) PPARGL3MBTL1LMNAPPARAPPARD
SCHEMBL14210007 0.81 ALDH1A1 (0.53) PPARGL3MBTL1LMNANR1H4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313717-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-10-17 EP disclosed
US-7176224-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2007-02-13 US disclosed
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
EP-1313717-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002016332-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARD, PPARG PPARG 3/4885L3MBTL1 4663/4885LMNA 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.